<DOC>
	<DOC>NCT02856542</DOC>
	<brief_summary>This study aims to describe the patient population being treated and evaluate their treatment adherence and treatment outcomes during treatment of scalp psoriasis with Daivobet® gel Applicator for 4 weeks.</brief_summary>
	<brief_title>Real-life Evaluation of the Daivobet® Gel Applicator</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Age ≥ 18 years Dermatologist or general practitioner has decided to initiate treatment with Daivobet® gel Applicator Indication not within the approved labelling in France Contraindication for treatment with calcipotriol or betamethasone dipropionate Informed consent to participate in the study has not been obtained</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Psoriasis vulgaris, scalp, topical, applicator, device</keyword>
</DOC>